Jeffrey P. Hodge

2.9k citations

39 papers · 2.3k indexed · 2 hit papers · h-index 20

Oncology top 2%
- Cancer Treatment and Pharmacology 8
- Colorectal Cancer Treatments and Studies 4
- Pancreatic and Hepatic Oncology Research 4
Reproductive Medicine top 5%
Immunology top 10%
Hematology top 5%
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 7
Cell Biology
- Microtubule and mitosis dynamics 11
Cancer Research
- Cancer Genomics and Diagnostics 6
Genetics
- Chronic Lymphocytic Leukemia Research 4
Molecular Biology
- Cancer therapeutics and mechanisms 4

Co-authors: Jia Xin Yu Vanessa M. Hubbard-LuceyJun TangSamik Upadhaya Cristina Oliva A. Benjamin Suttle Yunqing Lin Mohammed M. Dar
Cited by: Oncology Reproductive Medicine Immunology
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Jeffrey P. Hodge

38 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
2018 The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Peers

Countries citing papers authored by Jeffrey P. Hodge

Since Specialization

Citations

This map shows the geographic impact of Jeffrey P. Hodge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey P. Hodge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey P. Hodge more than expected).

Fields of papers citing papers by Jeffrey P. Hodge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey P. Hodge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey P. Hodge. The network helps show where Jeffrey P. Hodge may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jeffrey P. Hodge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeffrey P. Hodge Line = papers co-authored together Jeffrey P. Hodge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscapebreakdown → Samik Upadhaya,Svetoslav T. Neftelinov,Jeffrey P. Hodge,Jay Campbell	2022	134
2	Combinations take centre stage in PD1/PDL1 inhibitor clinical trials Samik Upadhaya,Svetoslav T. Neftelino,Jeffrey P. Hodge,Cristina Oliva,Jay R. Campbell,Jia Xin Yu	2020	123
3	The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitorsbreakdown → Jun Tang,Jia Xin Yu,Vanessa M. Hubbard-Lucey,Svetoslav T. Neftelinov,Jeffrey P. Hodge,Yunqing Lin	2018	301
4	Using real world data to evaluate overall survival in PD1-treated vs. standard of care metastatic melanoma patients. Purvi Dev-Vartak,Xinyan Yu,Faqiang Liu,Paul Cariola,Jeffrey P. Hodge,Vijayavarman Gopalakrishnan,Rolin L. Wade	2018	2
5	An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer Cornelius F. Waller,Ihor Vynnychenko,Igor Bondarenko,Yaroslav Shparyk,Jeffrey P. Hodge,Anne Freeman,Brian E. Huber,Ronald Lieberman,Mark Shelton,Harish P. Dave	2014	13
6	EP-1122: Patterns of care and outcome in HPV p16+ oropharyngeal squamous cell carcinoma treated at a tertiary hospital Michael X. Min,Raghu Gowda,Jasmine Micklem,de Roos,Michael Penniment,Gwyneth. Rees,Jeffrey P. Hodge,Beth E. Shubin Stein,A. Taylor,S. Krishnan	2014	1
7	Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors Maja J.A. de Jonge,Paul Hamberg,Jaap Verweij,S. Savage,A. Benjamin Suttle,Jeffrey P. Hodge,Thangam Arumugham,Lini Pandite,Herbert I. Hurwitz	2012	29
8	A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors Elisabeth I. Heath,E. Gabriela Chiorean,Christopher J. Sweeney,Jeffrey P. Hodge,Joanne Lager,Karen Forman,Lisa Malburg,Thangam Arumugham,Mohammed M. Dar,A. Benjamin Suttle,Shelby D. Gainer,Patricia LoRusso	2010	85
9	A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose Kyle D. Holen,Chandra P. Belani,George Wilding,Suresh S. Ramalingam,Jennifer Volkman,Ramesh K. Ramanathan,Lakshmi Vasist,Carolyn J. Bowen,Jeffrey P. Hodge,Mohammed M. Dar,Peter Ho	2010	60
10	An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors Brian C. Goh,Nandi J. Reddy,Uday B. Dandamudi,Kevin Laubscher,T Peckham,Jeffrey P. Hodge,A. Benjamin Suttle,Thangam Arumugham,Yanjun Xu,Chun‐Fang Xu,Joanne Lager,Mohammed M. Dar,Lionel D. Lewis	2010	72
11	A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors Howard A. Burris,Suzanne F. Jones,Daphne Williams,Steven J. Kathman,Jeffrey P. Hodge,Lini Pandite,Peter Ho,Scott A. Boerner,Patricia LoRusso	2010	52
12	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Michael Friedländer,Kenneth C. Hancock,Danny Rischin,Mark Messing,Claude A. Stringer,Gemma M. Matthys,Bo Ma,Jeffrey P. Hodge,Joanne Lager	2010	171
13	A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours Sarah P. Blagden,L. Rhoda Molife,A Seebaran,Miranda Payne,Alison Reid,Andrew Protheroe,Lakshmi Vasist,Daphne Williams,Chester L. Bowen,Steven J. Kathman,Jeffrey P. Hodge,Mohammed M. Dar,Johann S. de Bono,Mark R. Middleton	2008	63
14	A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression Steven J. Kathman,Daphne Williams,Jeffrey P. Hodge,Mohammed M. Dar	2008	12
15	A Bayesian Population PK–PD Model of Ispinesib-induced Myelosuppression Steven J. Kathman,Daphne Williams,Jeffrey P. Hodge,M. Dar	2006	18
16	Unexpected relationship between plasma protein binding and the pharmacodynamics of 2‐NAP, a CCK1‐receptor antagonist V.P. Gerskowitch,Jeffrey P. Hodge,Robert A. D. Hull,Nigel P. Shankley,S. Barret Kalindjian,John McEwen,J.W. Black	2006	8
17	Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. Sarah P. Blagden,A Seebaran,R. Molife,Miranda Payne,Alison Reid,Andrew Protheroe,Steven J. Kathman,Dallas Williams,Carolyn J. Bowen,Jeffrey P. Hodge,M. Dar,Johann S. de Bono,Mark R. Middleton	2005	1
18	Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies Joanne Kurtzberg,T J Ernst,Michael J. Keating,Varsha Gandhi,Jeffrey P. Hodge,David F. Kisor,Joanne Lager,Connie Stephens,Jay M. Levin,Thomas A. Krenitsky,Gertrude B. Elion,Beverly S. Mitchell	2005	129
19	Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days Howard A. Burris,Patricia LoRusso,Suzanne F. Jones,Tina Guthrie,J. B. Orr,Daphne Williams,Jeffrey P. Hodge,Mark Bush,James H. Sabry	2004	25
20	Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies David F. Kisor,William Plunkett,Joanne Kurtzberg,Beverly S. Mitchell,Jeffrey P. Hodge,Timothy J. Ernst,Michael J. Keating,Varsha Gandhi	2000	52

About Jeffrey P. Hodge

Jeffrey P. Hodge is a scholar working on Oncology, Cell Biology and Cancer Research, having authored 39 papers that have together received 2.3k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (11 papers), Cancer Treatment and Pharmacology (8 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer therapeutics and mechanisms (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). The work is most often cited by research in Oncology (1.3k citations), Reproductive Medicine (160 citations) and Immunology (400 citations). Jeffrey P. Hodge has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Jia Xin Yu, Vanessa M. Hubbard-Lucey, Jun Tang, Samik Upadhaya, Cristina Oliva, A. Benjamin Suttle, Yunqing Lin, Mohammed M. Dar, Lini Pandite and Joanne Lager.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact